YD Bio Ltd (YDES)
NASDAQ · Healthcare Services · Services-Medical Laboratories
- Price
- $4.77
- Day
- +47.68%
Close 2026-09-24.
The company
Business Overview We are a publicly listed biotechnology company focused on regulated diagnostics, life science clinical services, and healthcare product commercialization. Our operations include DNA methylation-based oncology testing programs in the United States conducted under a LDT framework in collaboration with CLIA-certified and CAP-accredited laboratory partners. In addition to our diagnostics activities, we provide regulated life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology companies, including procurement, logistics coordination, and compliance-focused support for clinical development programs. We also maintain ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia under applicable regulatory and market requirements. Through our combined diagnostics platform, clinical service infrastructure, and healthcare commercialization capabilities, we seek to develop a scalable operating model designed to support growth across multiple regulated healthcare segments.
From Item 1: Business Overview.
By product & service
- Sales Of Medical and Other Related Products — 94%
- Medical and Related Products — 47%
- Drugs — 37%
- Beauty Products — 8%
- Contact Lenses — 6%
- Research and Development Of Sales Of Contact Lenses — 6%
- Nutritional Products — 1%
- Supplements — 0%
Institutional holders
Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.
- Garrett Wealth Advisory Group, LLC — $190.42K
- GEODE CAPITAL MANAGEMENT, LLC — $141.11K
- Cypress Capital Management LLC (WY) — $75.8K
- Cerity Partners LLC — $72.91K
- CITADEL ADVISORS LLC — $67.74K
- JANE STREET GROUP, LLC — $39.22K
- UBS Group AG — $27.43K
- WOLVERINE ASSET MANAGEMENT LLC — $10.99K
Insider trades
Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.
- Shen Ethan PhD (CEO) bought 12,700 shares at $3.85 on 2026-09-14
- Shen Ethan PhD (CEO) bought 3,100 shares at $3.93 on 2026-09-09
- Shen Ethan PhD (CEO) bought 18,378 shares at $3.67 on 2026-09-04
Recent filings
- 4 — 2026-09-16
- 4 — 2026-09-10
- 4 — 2026-09-08
- 6-K — 2026-09-01
- 424B3 — 2026-09-01
- 424B3 — 2026-08-11
- 6-K — 2026-08-11
- 4 — 2026-07-01
- 4 — 2026-07-01
- EFFECT — 2026-05-29